MedDataX Logo

Risk Factors of Porphyria Cutanea Tarda (PCT)

NCT ID: NCT00213772

Last Updated: 2005-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

280 participants

Study Classification

OBSERVATIONAL

Study Start Date

1999-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.

Single blood + urine sample uptake to investigate : mutations in HFE gene, uroporphyrinogen decarboxylase activity, HCV genotye, history of disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Porphyria Cutanea Tarda

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Porphyria cutanea tarda hepatitis C hemochromatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Porphyria cutanea tarda /HCV negative Porphyria cutanea tarda/ HCV positive HCV positive HCV negative controls
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bernard Cribier, MD

Role: PRINCIPAL_INVESTIGATOR

Hopitaux Universitaires de Strasbourg

O. Chosidow, MD

Role: PRINCIPAL_INVESTIGATOR

Hopital Pitié-Salpétrière / Paris

M. Bagot, MD

Role: PRINCIPAL_INVESTIGATOR

Hopital Henri Mondor / CHU Créteil

J.P Lacour, MD

Role: PRINCIPAL_INVESTIGATOR

Hopital de l'Archet / CHU Nice

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2030

Identifier Type: -

Identifier Source: org_study_id